 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...144145146147148149150151152153154...235236» |
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Oct 12, 2020
P2, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=136 --> 78 | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2020
- | Trial completion date, Trial termination, Trial primary completion date: GABLE: Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers (clinicaltrials.gov) - Oct 12, 2020
P1, N=6, Terminated, Sponsor: Tannaz Armaghany
N=136 --> 78 | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2020 Trial completion date: Jan 2027 --> Jun 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Mar 2020; The PI has decided to close the study due to the outdated study design.
- leucovorin calcium / Generic mfg.
[VIRTUAL] Megaloblastic Anemia in a Patient on Peritoneal Dialysis Returning from Kenya (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_2952;
Treatment is based on discontinuing the drug, administration of folinic acid and supportive care. Data suggest proguanil is poorly dialyzable.
- | New P1 trial, Combination therapy: Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis (clinicaltrials.gov) - Oct 11, 2020
P1, N=30, Not yet recruiting, Sponsor: Johns Hopkins University
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
[VIRTUAL] SHORT AND LONG TERM HEPATIC STEATOTIC CHANGES ON CT IMAGING FOR PATIENTS UNDERGOING 5-FU BASED CHEMOTHERAPY FOR COLORECTAL CANCER () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1214;
Patient with prior hepatic steatosis became less steatotic, while patients without prior hepatic steatosis became more steatotic after 5-FU based chemotherapy. Differences in hepatic steatotic changes were not explained by variabilities in baseline BMI, AST, and ALT.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
[VIRTUAL] CLINICAL AND ECONOMIC BURDEN IN PATIENTS RECEIVING NCCN-RECOMMENDED SYSTEMIC THERAPY FOR METASTATIC HEPATOCELLULAR CARCINOMA () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1144;
This study suggests that pts with mHCC incur a significant clinical and economic burden in the first year after diagnosis in the US, irrespective of the systemic therapy used. As the treatment landscape evolves to include combination therapies, it would be interesting to use these findings as a benchmark for the relative costs associated with mHCC treatment and provide context for comparison with patients treated with newer combination therapies.
- ||| leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Retrospective data, Journal, Adverse events: Low Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Oct 11, 2020
This meta-analysis gives more precise estimates of mucocutaneous adverse effects that occur in rheumatic disease patients using MTX. These estimates will help inform patient decision making regarding MTX.
- [VIRTUAL] Circulating Tumor DNA (Ct DNA) as a Biomarker in HighGrade Gastroenteropancreatic Neuroendocrine Tumor (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_72;
P2
Acknowledgment: The trial is funded by Ipsen pharmaceuticals. Correlative studies are funded by the North American Neuroendocrine Tumor Society through the Clinical Investigator Scholarship.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Efficacy of FOLFOX With Or Without Bevacizumab in Patients With Aggressive Pancreatic NETs After Prior Capecitabine/Temozolomide (VIRTUAL POSTER HALL) - Oct 9, 2020 - Abstract #NANETS2020NANETS_30;
BACKGROUND: 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) has activity in pancreatic NETs, but its use is limited, partly due to side effects. FOLFOX ± bev is active in aggressive and heavily pretreated pancreatic NETs who have progressed on prior cap/tem chemotherapy, although response durations are relatively short.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first:line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1246;
P2, P3
Background Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase II (NCT01630083) results showed prolonged survival of patients (pts) with CLDN18.2+ advanced G/GEJ treated with zolbe + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...Funding: This study was funded by Astellas Pharma, Inc. Clinical trial identification: NCT03504397.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9 (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1241;
P1/2
Funding: Ipsen. Clinical trial identification: NCT02551991.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1239;
P1/2, P3
Funding: Ipsen. Clinical trial identification: NCT02551991.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci
[VIRTUAL] Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1221;
Legal entity responsible for the study: The authors. Funding: National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
- Tyvyt (sintilimab) / Eli Lilly
[VIRTUAL] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1209;
P2
Neoadjuvant combination of sintilimab and FOLT is a safe and efficacious treatment option for patients with gastric or GEJ adenocarcinoma, and 22.2% pCR rate is encouraging. Our clinical study (NCT04341857) is still enrolling, and the survival effects are under follow up.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in firstline Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_881;
P2, P3
Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase II (NCT01630083) results showed prolonged survival of patients (pts) with CLDN18.2+ advanced G/GEJ treated with zolbe + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...As of June 30, 2020, 190 sites have been initiated. This study was funded by Astellas Pharma, Inc.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] Firstline liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 199 (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_876;
P1/2
CA 19-9 is a potential biomarker of post-NALIRIFOX outcomes in these patients. Ipsen.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] Firstline liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_874;
P1/2, P3
The randomized phase III NAPOLI-3 study (NCT04083235) will compare NALIRIFOX with gemcitabine + nab-paclitaxel. Ipsen.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci
[VIRTUAL] Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_856;
Triple combination therapy of lenvatinib, toripalimab, and HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced HCC. National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
- Tyvyt (sintilimab) / Eli Lilly
[VIRTUAL] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_844;
P2
Neoadjuvant combination of sintilimab and FOLT is a safe and efficacious treatment option for patients with gastric or GEJ adenocarcinoma, and 22.2% pCR rate is encouraging. Our clinical study (NCT04341857) is still enrolling, and the survival effects are under follow up.
- zolbetuximab (IMAB362) / Astellas
[VIRTUAL] SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in firstline Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_508;
P2, P3
Fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) is accepted first-line therapy for advanced/metastatic G/GEJ...Phase II (NCT01630083) results showed prolonged survival of patients (pts) with CLDN18.2+ advanced G/GEJ treated with zolbe + epirubicin, oxaliplatin, and capecitabine (EOX) vs EOX alone...As of June 30, 2020, 190 sites have been initiated. This study was funded by Astellas Pharma, Inc.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] Firstline liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 199 (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_503;
P1/2
CA 19-9 is a potential biomarker of post-NALIRIFOX outcomes in these patients. Ipsen.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] Firstline liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_501;
P1/2, P3
The randomized phase III NAPOLI-3 study (NCT04083235) will compare NALIRIFOX with gemcitabine + nab-paclitaxel. Ipsen.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci
[VIRTUAL] Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_483;
Triple combination therapy of lenvatinib, toripalimab, and HAIC had acceptable toxic effects and might improve survival compared with lenvatinib alone in advanced HCC. National Natural Science Foundation of China Ministry of Science and Technology of the People's Republic of China.
- Tyvyt (sintilimab) / Eli Lilly
[VIRTUAL] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_471;
P2
Neoadjuvant combination of sintilimab and FOLT is a safe and efficacious treatment option for patients with gastric or GEJ adenocarcinoma, and 22.2% pCR rate is encouraging. Our clinical study (NCT04341857) is still enrolling, and the survival effects are under follow up.
- | Trial completion date, Trial primary completion date, Combination therapy: Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI (clinicaltrials.gov) - Oct 8, 2020
P1, N=16, Recruiting, Sponsor: University of Massachusetts, Worcester
Our clinical study (NCT04341857) is still enrolling, and the survival effects are under follow up. Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma (clinicaltrials.gov) - Oct 8, 2020
P2, N=63, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2025 | Trial primary completion date: Sep 2020 --> Sep 2021
- ||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 8, 2020
P1, N=240, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Sep 2025 | Trial primary completion date: Sep 2020 --> Sep 2021 Active, not recruiting --> Completed
- ||| BOLD-100 / Bold Therap
Enrollment open, Combination therapy, Metastases: BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrials.gov) - Oct 7, 2020
P1b, N=80, Recruiting, Sponsor: Bold Therapeutics, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Clinical, Journal, HEOR: Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. (Pubmed Central) - Oct 7, 2020
P3
In scenario 2, when the value-based price was adopted, panitumumab plus FOLFIRI was estimated to be cost-effective. Our study establishes a pricing framework for new anticancer drugs to reflect the economics of drugs.
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] RESPONSE TO AND SURVIVAL AFTER FIRST-LINE FOLFIRINOX OR GEMCITABINE/NABPACLITAXEL FOR LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA () - Oct 7, 2020 - Abstract #APCM2020APCM_61;
Background: 5-Fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel (GA) are first-line chemotherapy regimens for pancreatic cancer. In this cohort of patients with localized pancreatic adenocarcinoma who received FOLFIRINOX or GA as their first line of therapy, FOLFIRINOX was associated with higher rates of RECIST PR and subsequent pancreatectomy than GA but the overall survival associated with these regimens was similar.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
[VIRTUAL] AGGRESSIVE SURGERY FOR SELECTED PATIENTS WITH PANCREATIC CANCER AND ISOLATED LIVER METASTASIS () - Oct 7, 2020 - Abstract #APCM2020APCM_15;
In selected patients with pancreatic cancer and isolated liver metastasis, surgical resection of the pancreatic and liver tumors can result in meaningful survival. Prospective trials to evaluate the role of aggressive surgery in such patients are Warranted.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, P2 data, Journal: Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma; a prospective phase 2 trial. (Pubmed Central) - Oct 7, 2020
Tumor reduction using an initial LD-CCRT enabled down-staging, subsequent curative treatment, and long-term survival in about 20% of the patients with advanced HCC. However, further randomized trials are required to confirm these results.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Observational data, Journal: Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. (Pubmed Central) - Oct 7, 2020
The majority of patients were treated with the combination of nab-paclitaxel-gemcitabine (NPG), 5-fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), or gemcitabine monotherapy...The majority received NPG, FOLFIRINOX/capecitabine, oxaliplatin, irinotecan (CAPOXIRI), or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX)/capecitabine, oxaliplatin (CAPOX)...This study described the significant improvement in prognosis of PAC patients receiving palliative chemotherapy and the relatively high rate of receipt of second-line chemotherapy, according to real-world data. However, due to the nonrandomized nature of the study, any comparison between different chemotherapy regimens should be regarded with caution.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer. (Pubmed Central) - Oct 7, 2020
However, due to the nonrandomized nature of the study, any comparison between different chemotherapy regimens should be regarded with caution. Patients with RAS-mt mCRC whose plasma biopsies contained RAS-wt could benefit from cetuximab-based therapy, a hypothesis to be tested in a prospective randomized trial.
- | Trial completion date, Trial primary completion date, Metastases: ChanghaiH-PP05: Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 5, 2020
P1/2, N=60, Recruiting, Sponsor: Changhai Hospital
Patients with RAS-mt mCRC whose plasma biopsies contained RAS-wt could benefit from cetuximab-based therapy, a hypothesis to be tested in a prospective randomized trial. Trial completion date: Oct 2020 --> Nov 2023 | Trial primary completion date: Jul 2020 --> Nov 2022
- || Trial completion date, Trial primary completion date, Liquid biopsy, Biopsy: Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial (clinicaltrials.gov) - Oct 5, 2020
P2, N=140, Recruiting, Sponsor: IFOM, The FIRC Institute of Molecular Oncology
Trial completion date: Oct 2020 --> Nov 2023 | Trial primary completion date: Jul 2020 --> Nov 2022 Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- | Trial primary completion date, Surgery: CALGB: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery (clinicaltrials.gov) - Oct 5, 2020
P3, N=2500, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Trial primary completion date: Sep 2020 --> Feb 2020
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Oct 5, 2020
P2, N=43, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: Sep 2020 --> Feb 2020 Trial primary completion date: May 2020 --> Jul 2021
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Oct 5, 2020
P2, N=136, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2020 --> Jul 2021 Trial completion date: Jun 2022 --> Sep 2021
- | Enrollment open: A021806: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer (clinicaltrials.gov) - Oct 4, 2020
P3, N=352, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Jun 2022 --> Sep 2021 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: IMMUNOX: FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 4, 2020
P2, N=30, Recruiting, Sponsor: Dorte Nielsen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Journal: Advances in the treatment of gastric cancer: 2019. (Pubmed Central) - Oct 4, 2020
Two-drug chemotherapy is the optimal initial treatment in metastatic disease. Adding pembrolizumab to front-line chemotherapy did not improve survival, with use of immune checkpoint inhibitors reserved to treat chemotherapy refractory metastatic disease.
- [VIRTUAL] The Cost-Effectiveness of Liposomal Irinotecan and 5-Fluorouracil (5-FU)/ Leucovorin (LV) for the Treatment of Patients with Metastatic Adenocarcinoma of Pancreas WHO Have Progressed Following the Use of Gemcitabine-Related Therapies in Gre ... () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_834;
Adding pembrolizumab to front-line chemotherapy did not improve survival, with use of immune checkpoint inhibitors reserved to treat chemotherapy refractory metastatic disease. The present economic evaluation suggests that nal-IRI+5-FU/LV, a therapy that provides survival benefits to patients with mPDAC after disease progression following gemcitabine-based treatment, was estimated to be a good value for money treatment option for the Greek patients.
- leucovorin calcium / Generic mfg., Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combining Sorafenib for Advanced Hepatocellular Carcinoma in China () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_642;
CONCLUSIONS : The study results indicate that SoraHAIC is not cost-effective at a WTP threshold of $30,492/QALY representative across allof China. In developed areas of China (Beijing), there was a 38.8%probability that the SoraHAIC regimen would be cost-effective.
- || Clinical, Journal: Clinical assessment of 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan(FOLFIRABRAX) in untreated gastrointestinal cancer patients using UGT1A1 genotype-guided dosing. (Pubmed Central) - Oct 3, 2020
Too few *28/*28 patients were enrolled to provide conclusive results. Responses occurred across multiple tumor types.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Journal, IO Biomarker: Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. (Pubmed Central) - Oct 3, 2020
Importantly, FMT did not cause bacteremia and safely alleviated FOLFOX-induced intestinal mucositis in colorectal cancer-bearing mice. The putative mechanism may involve the gut microbiota TLR-MyD88-NF-κB signaling pathway in mice with implanted colorectal carcinoma cells.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal, HEOR: Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients. (Pubmed Central) - Oct 2, 2020
An iNMB of -€23,189 was found for 3 months versus 6 months. Our findings indicate that 3 months' adjuvant chemotherapy should be considered as standard of care in high-risk stage II CC patients for CAPOX, but not for FOLFOX.
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial primary completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Oct 1, 2020
P2, N=136, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Our findings indicate that 3 months' adjuvant chemotherapy should be considered as standard of care in high-risk stage II CC patients for CAPOX, but not for FOLFOX. Trial primary completion date: Sep 2020 --> Sep 2021
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Oct 1, 2020
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2020 --> Sep 2021 Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Journal: FOLFIRI-Mediated Toxicity in Human Aortic Smooth Muscle Cells and Possible Amelioration with Curcumin and Quercetin. (Pubmed Central) - Oct 1, 2020
Our study presents two preliminary findings: (a) in HaVSMCs, FOLFIRI treatment significantly induces oxidative damage to both DNA and protein, leading to a dramatic increase in caspase-dependent apoptotic death through P53-mediated Caspase3-dependent mitochondrial apoptosis, and results in TNF-α/Caspase8-mediated necrotic death, and (b) flavonoids not only regulate the expression of genes encoding antioxidant enzymes and increase DNA damage but also limit programmed and necrotic cell death processes in HaVSMCs. Our results clearly indicate the potential for curcumin and, particularly, quercetin as preventative chemotherapeutic interventions for cardiovascular toxicity induced by the FOLFIRI regime in HaVSMCs.